A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Completed · Phase 2 · NCT03332017
Conditions: Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $49,815
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 217
About the trial
- Sponsor
- BeiGene
- Tested
- Zanubrutinib (drug), Obinutuzumab (drug)
- Dates
- Started 2017-11-14; completion 2024-12-27
- Results posted
- Yes
This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior therapy.
From ClinicalTrials.gov, last updated 2026-02-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $49,815 in research payments for this study in 2025 (21 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jonathon B. Cohen, M.D. Hematology & Oncology · Atlanta, GA
- Matthew S. Mckinney, M.D. Hematology & Oncology · Durham, NC
- Edwin C. Kingsley, MD Hematology & Oncology · Las Vegas, NV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Comprehensive Cancer Centers of Nevada - Central Valley $21,762
- Emory University Hospital, GA $13,636
- Duke University , $9,262
- University of Illinois Hospital and Clinics, IL $5,155
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.